Sigma Tau Research Switzerland SA
Leadiant Biosciences, Inc. is a U.S. research-based pharmaceutical company dedicated to the research, development, and distribution of therapies for patients with rare diseases. Based in Rockville, Maryland, the company focuses on bringing novel therapies to market, supporting patients and their families with education and resources, and reinvesting in research to develop therapies with real clinical value. Owned by Essetifin S.p.A., Leadiant operates in the U.S. and Europe, with region-specific product information available on respective websites.
Industries
Nr. of Employees
large (251-1000)
Sigma Tau Research Switzerland SA
Patents
Products
Abelcet (amphotericin B lipid-complex injection)
Amphotericin B formulated as a lipid-complex injectable for therapeutic use.
Carnitor (levocarnitine)
Levocarnitine provided as a marketed therapeutic product.
Cystaran (cysteamine ophthalmic solution) 0.44%
Cysteamine formulated as a 0.44% ophthalmic solution for topical ocular use.
Matulane (procarbazine hydrochloride)
Procarbazine hydrochloride provided as a marketed therapeutic product.
Abelcet (amphotericin B lipid-complex injection)
Amphotericin B formulated as a lipid-complex injectable for therapeutic use.
Carnitor (levocarnitine)
Levocarnitine provided as a marketed therapeutic product.
Cystaran (cysteamine ophthalmic solution) 0.44%
Cysteamine formulated as a 0.44% ophthalmic solution for topical ocular use.
Matulane (procarbazine hydrochloride)
Procarbazine hydrochloride provided as a marketed therapeutic product.
Services
Joint research and development with physicians, researchers, and academic biotechnology organizations to advance product candidates for rare diseases.
Provision of educational materials, resources, registries, and support programs aimed at patients and caregivers affected by rare diseases.
Online resources and compliance documentation for healthcare professionals, aligned with applicable industry interaction standards.
Organization-level compliance program with public declarations, adherence to healthcare laws and codes, and anonymous reporting channels.
Operational delivery of therapies to patients, including programs and channels that support access to marketed treatments.
Joint research and development with physicians, researchers, and academic biotechnology organizations to advance product candidates for rare diseases.
Provision of educational materials, resources, registries, and support programs aimed at patients and caregivers affected by rare diseases.
Online resources and compliance documentation for healthcare professionals, aligned with applicable industry interaction standards.
Organization-level compliance program with public declarations, adherence to healthcare laws and codes, and anonymous reporting channels.
Operational delivery of therapies to patients, including programs and channels that support access to marketed treatments.
Expertise Areas
- Rare disease drug development
- Clinical trial engagement and patient recruitment
- Research collaboration and translational partnerships
- Regulatory compliance and corporate ethics programs
Key Technologies
- Lipid-complex injectable formulation
- Ophthalmic solution formulation
- Small-molecule therapeutic development
- Patient registry and clinical data collection systems